|
186 Companies |
|
243 Products |
|
243 Products |
|
92 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...41424344454647484950515253» |
- | Jakafi (ruxolitinib) / Novartis, Incyte
New P4 trial, P2 data: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (clinicaltrials.gov) - Mar 18, 2012
P4, N=48, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- bendamustine / Generic mfg.
Trial termination: Bendamustine in Acute Leukemia and MDS (clinicaltrials.gov) - Mar 14, 2012
P1/2, N=27, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Lack of Response
- bendamustine / Generic mfg.
Trial initiation date: Bendamustine in Acute Leukemia and MDS (clinicaltrials.gov) - Mar 14, 2012
P1/2, N=27, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Lack of Response Initiation date: May 2008 --> Nov 2008
- bendamustine / Generic mfg.
Enrollment change: Bendamustine in Acute Leukemia and MDS (clinicaltrials.gov) - Mar 14, 2012
P1/2, N=27, Terminated, Sponsor: M.D. Anderson Cancer Center
Initiation date: May 2008 --> Nov 2008 N=153 --> 27
- Enrollment open, Metastases: AHN-12 Biodistribution in Advanced Leukemia (clinicaltrials.gov) - Mar 13, 2012
P1, N=30, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=153 --> 27 Suspended --> Recruiting
- | Trial completion: Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer (clinicaltrials.gov) - Mar 13, 2012
P2, N=44, Completed, Sponsor: Case Comprehensive Cancer Center
Suspended --> Recruiting Active, not recruiting --> Completed
- Trial completion, HEOR: Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=168, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy: Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) (clinicaltrials.gov) - Mar 12, 2012
P1, N=71, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases (clinicaltrials.gov) - Mar 7, 2012
P=N/A, N=86, Completed, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Recruiting --> Completed
- fresolimumab (GC 1008) / Sanofi
Enrollment change: Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) - Mar 7, 2012
P1, N=3, Completed, Sponsor: John Mascarenhas
Recruiting --> Completed N=14 --> 3
- |||||| Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment open: PHCHBS-WD4070: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase) (clinicaltrials.gov) - Mar 6, 2012
P3, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
N=14 --> 3 Active, not recruiting --> Recruiting
- Trial completion: T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Mar 6, 2012
P1, N=20, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Mar 6, 2012
P1/2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P4 trial: Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia (clinicaltrials.gov) - Mar 5, 2012
P4, N=64, Completed, Sponsor: Novartis Pharmaceuticals
- Enrollment closed: Tissue Sample Collection From Patients With Fanconi Anemia (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=120, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Combination therapy: A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia (clinicaltrials.gov) - Mar 5, 2012
P1, N=23, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- decitabine / Generic mfg.
Trial termination: Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis (clinicaltrials.gov) - Mar 4, 2012
P2, N=4, Terminated, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Terminated; Stopped due to slow accrual
- decitabine / Generic mfg.
Enrollment change: Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis (clinicaltrials.gov) - Mar 4, 2012
P2, N=4, Terminated, Sponsor: Mayo Clinic
Active, not recruiting --> Terminated; Stopped due to slow accrual N=22 --> 4
- | Trial completion: Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (clinicaltrials.gov) - Mar 4, 2012
P3, N=1337, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
N=22 --> 4 Active, not recruiting --> Completed
- deferasirox tablet for oral suspension / Generic mfg.
Trial initiation date: MACS1574: Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (clinicaltrials.gov) - Feb 29, 2012
P4, N=12, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Dec 2011
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Trial initiation date, Metastases: Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone (clinicaltrials.gov) - Feb 29, 2012
P2, N=46, Recruiting, Sponsor: David C Smith
Initiation date: Jul 2011 --> Dec 2011 Initiation date: Oct 2011 --> Feb 2012
- New P2 trial: TevaGastrim for Stem Cell Mobilization Sibling Donors (clinicaltrials.gov) - Feb 29, 2012
P2, N=24, Active, not recruiting, Sponsor: Sheba Medical Center
- Leukine (sargramostim) / Partner Therap
New P2 trial: Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 29, 2012
P2, N=8, Terminated, Sponsor: M.D. Anderson Cancer Center
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Enrollment open, Metastases: Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone (clinicaltrials.gov) - Feb 29, 2012
P2, N=46, Recruiting, Sponsor: David C Smith
Initiation date: Oct 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- | Inrebic (fedratinib) / BMS
Enrollment closed: Phase 2 Study of SAR302503 in Patients With Myelofibrosis (clinicaltrials.gov) - Feb 29, 2012
P2, N=30, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Pegasys (pegylated interferon α -2a) / Roche
Enrollment open: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (clinicaltrials.gov) - Feb 28, 2012
P2, N=188, Recruiting, Sponsor: Ronald Hoffman
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 27, 2012
P1/2, N=69, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment open: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Feb 23, 2012
P1, N=18, Recruiting, Sponsor: Robert Lowsky
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- BMS-936559 / BMS
Trial withdrawal: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (clinicaltrials.gov) - Feb 21, 2012
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- BMS-936559 / BMS
Enrollment change: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (clinicaltrials.gov) - Feb 21, 2012
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Withdrawn N=110 --> 0
- pentostatin / Generic mfg.
Enrollment change: Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (clinicaltrials.gov) - Feb 21, 2012
P3, N=6, Completed, Sponsor: St. Jude Children's Research Hospital
N=110 --> 0 N=165 --> 6
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
N=165 --> 6 N=60 --> 32
- pentostatin / Generic mfg.
Trial completion: Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (clinicaltrials.gov) - Feb 21, 2012
P3, N=6, Completed, Sponsor: St. Jude Children's Research Hospital
N=60 --> 32 Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- MK-8776 / Merck (MSD)
Trial termination, Combination therapy: Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) (clinicaltrials.gov) - Feb 20, 2012
P1, N=24, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Completed --> Terminated
- | busulfan / Generic mfg., clofarabine / Generic mfg.
Trial completion: Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen (clinicaltrials.gov) - Feb 20, 2012
P2, N=20, Completed, Sponsor: Baylor Research Institute
Completed --> Terminated Active, not recruiting --> Completed
- cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion: Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS (clinicaltrials.gov) - Feb 20, 2012
P2, N=30, Completed, Sponsor: Baylor Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Feb 19, 2012
P1, N=7, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=35 --> 7
- Zokinvy (lonafarnib) / Eiger
Enrollment change: Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 19, 2012
P1, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=35 --> 7 N=75 --> 23
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Feb 18, 2012
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=75 --> 23 Recruiting --> Active, not recruiting
- | Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment closed: Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML (clinicaltrials.gov) - Feb 17, 2012
P1/2, N=35, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Tasigna (nilotinib) / Novartis, Inhibikase
New P3 trial: Nilotinib in PH+, BCR-, ABL+ CML Patients (clinicaltrials.gov) - Feb 15, 2012
P3, N=109, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- Enrollment closed: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Feb 15, 2012
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 15, 2012
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | StemEx (carlecortemcel-L) / Gamida Cell
Enrollment closed: ExCell: Efficacy and Safety Study of StemEx (clinicaltrials.gov) - Feb 14, 2012
P2/3, N=100, Active, not recruiting, Sponsor: Gamida Cell -Teva Joint Venture Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Biomarker, Enrollment closed: Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- Biomarker, Trial completion: Blood Samples to Evaluate Biomarkers of Donor Chimerism (clinicaltrials.gov) - Feb 12, 2012
P=N/A, N=80, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | tasisulam (LY573636) / Eli Lilly
Trial completion: Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 9, 2012
P1, N=45, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Amevive (alefacept) / Astellas
Trial suspension: Alefacept in Patients With Relapsed/Refractory Aplastic Anemia (clinicaltrials.gov) - Feb 7, 2012
P1/2, N=56, Suspended, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Recruiting --> Suspended
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia (clinicaltrials.gov) - Feb 7, 2012
P2, N=20, Completed, Sponsor: The Cleveland Clinic
Recruiting --> Suspended Active, not recruiting --> Completed